Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young Women

Gloria Y F Ho, Yevgeniy Y. Studentsov, Robert Bierman, Robert D. Burk

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Immunization with a vaccine of human papillomavirus (HPV) type 16 virus-like particles (VLPs) can reduce incidence of HPV-16 infection and its related cervical intraepithelial neoplasia. However, development of detectable antibodies to VLPs does not always occur after natural HPV infection. This study examined prospectively for seroconversion and duration of antibodies to HPV-16 VLPs and their associated host and viral factors. Six-hundred eight subjects were tested for HPV DNA biannually and for IgG and IgA antibodies to HPV-16 VLPs annually for 3 years. Both IgG and IgA antibodies to HPV-16 VLPs were predominantly type specific. Women with cervicovaginal HPV-16 infection were 8-10 times more likely to seroconvert than those with infection of HPV-16-related types. Among subjects who had an incident infection with HPV-16, a maximum of 56.7% became seropositive for IgG within 8.3 months and 37.0% had IgA within 14 months. Detectable seroconversion was a slow process that required sufficient antigenic exposure associated with either a high viral load (relative risk = 5.7 for IgG) or persistent infection of HPV-16 (relative risk = 3.4 for IgA). The median duration for both types of antibodies was ∼36 months. Antibodies could persist for a long period of time if the initial antibody levels were high or if there was continued antigenic exposure.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume13
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Human papillomavirus 16
Natural History
Virion
Papillomaviridae
Antibodies
Immunoglobulin A
Papillomavirus Infections
Immunoglobulin G
Infection
Cervical Intraepithelial Neoplasia
Viral Load
Immunization
Vaccines
DNA
Incidence

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young Women. / Ho, Gloria Y F; Studentsov, Yevgeniy Y.; Bierman, Robert; Burk, Robert D.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 13, No. 1, 01.2004, p. 110-116.

Research output: Contribution to journalArticle

Ho, Gloria Y F ; Studentsov, Yevgeniy Y. ; Bierman, Robert ; Burk, Robert D. / Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young Women. In: Cancer Epidemiology Biomarkers and Prevention. 2004 ; Vol. 13, No. 1. pp. 110-116.
@article{039c4785960045e79d2846ec30092afc,
title = "Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young Women",
abstract = "Immunization with a vaccine of human papillomavirus (HPV) type 16 virus-like particles (VLPs) can reduce incidence of HPV-16 infection and its related cervical intraepithelial neoplasia. However, development of detectable antibodies to VLPs does not always occur after natural HPV infection. This study examined prospectively for seroconversion and duration of antibodies to HPV-16 VLPs and their associated host and viral factors. Six-hundred eight subjects were tested for HPV DNA biannually and for IgG and IgA antibodies to HPV-16 VLPs annually for 3 years. Both IgG and IgA antibodies to HPV-16 VLPs were predominantly type specific. Women with cervicovaginal HPV-16 infection were 8-10 times more likely to seroconvert than those with infection of HPV-16-related types. Among subjects who had an incident infection with HPV-16, a maximum of 56.7{\%} became seropositive for IgG within 8.3 months and 37.0{\%} had IgA within 14 months. Detectable seroconversion was a slow process that required sufficient antigenic exposure associated with either a high viral load (relative risk = 5.7 for IgG) or persistent infection of HPV-16 (relative risk = 3.4 for IgA). The median duration for both types of antibodies was ∼36 months. Antibodies could persist for a long period of time if the initial antibody levels were high or if there was continued antigenic exposure.",
author = "Ho, {Gloria Y F} and Studentsov, {Yevgeniy Y.} and Robert Bierman and Burk, {Robert D.}",
year = "2004",
month = "1",
doi = "10.1158/1055-9965.EPI-03-0191",
language = "English (US)",
volume = "13",
pages = "110--116",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young Women

AU - Ho, Gloria Y F

AU - Studentsov, Yevgeniy Y.

AU - Bierman, Robert

AU - Burk, Robert D.

PY - 2004/1

Y1 - 2004/1

N2 - Immunization with a vaccine of human papillomavirus (HPV) type 16 virus-like particles (VLPs) can reduce incidence of HPV-16 infection and its related cervical intraepithelial neoplasia. However, development of detectable antibodies to VLPs does not always occur after natural HPV infection. This study examined prospectively for seroconversion and duration of antibodies to HPV-16 VLPs and their associated host and viral factors. Six-hundred eight subjects were tested for HPV DNA biannually and for IgG and IgA antibodies to HPV-16 VLPs annually for 3 years. Both IgG and IgA antibodies to HPV-16 VLPs were predominantly type specific. Women with cervicovaginal HPV-16 infection were 8-10 times more likely to seroconvert than those with infection of HPV-16-related types. Among subjects who had an incident infection with HPV-16, a maximum of 56.7% became seropositive for IgG within 8.3 months and 37.0% had IgA within 14 months. Detectable seroconversion was a slow process that required sufficient antigenic exposure associated with either a high viral load (relative risk = 5.7 for IgG) or persistent infection of HPV-16 (relative risk = 3.4 for IgA). The median duration for both types of antibodies was ∼36 months. Antibodies could persist for a long period of time if the initial antibody levels were high or if there was continued antigenic exposure.

AB - Immunization with a vaccine of human papillomavirus (HPV) type 16 virus-like particles (VLPs) can reduce incidence of HPV-16 infection and its related cervical intraepithelial neoplasia. However, development of detectable antibodies to VLPs does not always occur after natural HPV infection. This study examined prospectively for seroconversion and duration of antibodies to HPV-16 VLPs and their associated host and viral factors. Six-hundred eight subjects were tested for HPV DNA biannually and for IgG and IgA antibodies to HPV-16 VLPs annually for 3 years. Both IgG and IgA antibodies to HPV-16 VLPs were predominantly type specific. Women with cervicovaginal HPV-16 infection were 8-10 times more likely to seroconvert than those with infection of HPV-16-related types. Among subjects who had an incident infection with HPV-16, a maximum of 56.7% became seropositive for IgG within 8.3 months and 37.0% had IgA within 14 months. Detectable seroconversion was a slow process that required sufficient antigenic exposure associated with either a high viral load (relative risk = 5.7 for IgG) or persistent infection of HPV-16 (relative risk = 3.4 for IgA). The median duration for both types of antibodies was ∼36 months. Antibodies could persist for a long period of time if the initial antibody levels were high or if there was continued antigenic exposure.

UR - http://www.scopus.com/inward/record.url?scp=1642527944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642527944&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-03-0191

DO - 10.1158/1055-9965.EPI-03-0191

M3 - Article

VL - 13

SP - 110

EP - 116

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 1

ER -